BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17851129)

  • 1. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.
    Ramírez de Molina A; Sarmentero-Estrada J; Belda-Iniesta C; Tarón M; Ramírez de Molina V; Cejas P; Skrzypski M; Gallego-Ortega D; de Castro J; Casado E; García-Cabezas MA; Sánchez JJ; Nistal M; Rosell R; González-Barón M; Lacal JC
    Lancet Oncol; 2007 Oct; 8(10):889-97. PubMed ID: 17851129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers.
    Yeh KT; Wu YH; Lee MC; Wang L; Li CT; Chen CY; Lee H
    Ann Surg Oncol; 2012 Mar; 19(3):734-42. PubMed ID: 21861227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
    Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
    J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
    Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
    Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
    Casali C; Cucca M; Rossi G; Barbieri F; Iacuzio L; Bagni B; Uliano M
    Lung Cancer; 2010 Aug; 69(2):187-93. PubMed ID: 19942313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
    Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
    Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
    Shintani Y; Ohta M; Hirabayashi H; Tanaka H; Iuchi K; Nakagawa K; Maeda H; Kido T; Miyoshi S; Matsuda H
    Lung Cancer; 2004 Aug; 45(2):189-96. PubMed ID: 15246190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
    Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM
    Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
    Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
    J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer.
    Chen CY; Hsu CP; Hsu NY; Shih CS; Lin TY; Chow KC
    Oncol Rep; 2002; 9(3):515-9. PubMed ID: 11956619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
    Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
    Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A five-gene signature and clinical outcome in non-small-cell lung cancer.
    Chen HY; Yu SL; Chen CH; Chang GC; Chen CY; Yuan A; Cheng CL; Wang CH; Terng HJ; Kao SF; Chan WK; Li HN; Liu CC; Singh S; Chen WJ; Chen JJ; Yang PC
    N Engl J Med; 2007 Jan; 356(1):11-20. PubMed ID: 17202451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.